Quantum Biopharma (QNTM) Retained Earnings (2018 - 2026)

Quantum Biopharma has disclosed Retained Earnings across 9 years of filings, most recently posting -$211.8 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$211.8 million, down 17.24% year-over-year; the trailing twelve-month figure through Mar 2026 was -$211.8 million (down 17.24% YoY), and the FY2025 annual result was -$198.3 million, down 15.21% from the prior year.
• Retained Earnings came in at -$211.8 million for Q1 2026 at Quantum Biopharma, down from -$198.3 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$127.8 million in Q1 2022 to a low of -$211.8 million in Q1 2026.
• The 5-year median for Retained Earnings is -$162.9 million (2024), against an average of -$165.4 million.
• Across the five-year window, Retained Earnings slipped 26.77% in 2022 and fell 4.84% in 2024, its largest moves.
• Quantum Biopharma's Retained Earnings stood at -$144.2 million in 2022, then dropped by 8.56% to -$156.5 million in 2023, then slipped by 9.97% to -$172.1 million in 2024, then declined by 15.21% to -$198.3 million in 2025, then retreated by 6.84% to -$211.8 million in 2026.
• The last three Retained Earnings figures came in at -$211.8 million (Q1 2026), -$198.3 million (Q4 2025), and -$195.3 million (Q3 2025), per Business Quant data.